su-6668

Orantinib (NSC 702827) , a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It shows little effect against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2 and does not suppresses EGFR.

SU9518, a tyrosine kinase inhibitor with PDGFRα specificity, can inhibit the development of proliferative vitreoretinopathy (PVR) in fibroblast and Müller cell rabbit models.

(Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.